- Tension: Dementia diagnosis has required expensive brain scans and spinal taps — tools unavailable across much of Latin America — while the research validating cheaper alternatives has been conducted almost entirely in European-descent populations.
- Noise: Blood biomarker research is often framed as a universal breakthrough without confronting the fact that most studies exclude the genetically diverse populations who need accessible diagnostics most.
- Direct Message: A landmark study across six Latin American countries proves blood tests can detect dementia with high accuracy in underrepresented populations — revealing that the barrier to diagnosis was never biological, but structural.
To learn more about our editorial approach, explore The Direct Message methodology.
For most of the world’s population, an Alzheimer’s diagnosis still requires technology that doesn’t exist in their nearest hospital. Brain scans. Spinal taps. Specialists who trained at institutions thousands of miles away. Recent research is challenging that reality — demonstrating that simple blood tests can detect Alzheimer’s disease and frontotemporal lobar degeneration in Latin American populations with striking accuracy, potentially reshaping who gets diagnosed and who gets left behind.
The numbers alone demand attention. Blood tests identified Alzheimer’s disease with high accuracy, and frontotemporal lobar degeneration — a less common but devastating form of dementia — with similarly strong results. When researchers combined those blood tests with brain imaging and cognitive assessments, accuracy improved further for both conditions. These aren’t theoretical projections. They’re results from volunteers recruited across memory clinics in multiple Latin American countries.
What makes this study different from the growing body of blood-biomarker research is who it studied. Participants included populations with diverse genetic backgrounds, according to the researchers — populations that have been systematically excluded from the clinical trials and datasets that shape modern diagnostic tools. Most existing blood-based biomarker research has been validated primarily in populations of European descent. The implicit assumption baked into those studies — that what works for one genetic background works for all — is exactly the kind of blind spot that perpetuates inequities in diagnosis and care.
The study measured key proteins in blood samples — amyloid, tau, and neurofilament light chain — that serve as biological markers for brain disease. Modified versions of the tau protein emerged as strong indicators of Alzheimer’s disease, while the neurofilament light chain protein proved effective for detecting frontotemporal lobar degeneration. Machine learning algorithms analyzed the protein patterns and predicted diagnoses — an approach that scales far more easily than training new neurologists in resource-limited settings.
As researchers in the field have noted, combining biomarkers with cognitive and neuroimaging markers in diverse populations is essential to avoid misdiagnosis and to ensure fair access to care. Otherwise, even the most advanced tools risk reinforcing existing health inequalities. That observation carries a weight that extends well beyond Latin America. It names something the global health community has been slow to confront — that precision medicine, without diversity in its evidence base, becomes precision medicine for some people.
The practical implications are enormous. Traditional dementia diagnosis requires expensive brain scans or invasive spinal taps, according to the researchers — procedures that are often unavailable in lower-income regions. A blood draw, by contrast, is among the most routine medical procedures on earth. Nearly every clinic, in every country, can draw blood. The barrier to Alzheimer’s diagnosis has never been biological. It’s been economic and infrastructural. This study suggests that barrier may be collapsing.
Experts in dementia research have emphasized the broader diagnostic philosophy at play: blood-based tests have enormous potential to transform dementia diagnosis. Integrating biological, cognitive, and physical measurements provides a much clearer picture of a patient’s health. The combined approach — blood biomarkers layered with imaging and cognitive testing — represents what researchers describe as using multiple types of evidence. It’s not a single test replacing everything. It’s a system of converging evidence, where a blood test opens the door and additional tools sharpen the picture.
This matters urgently because dementia is not distributed equally across the globe, but research funding and diagnostic infrastructure are. Latin America faces a rapidly aging population with caregiving burdens that already strain families and health systems. Alzheimer’s disease is widely recognized as the most frequent cause of dementia in older adults, and early diagnosis — the kind that changes treatment timelines and family planning — has historically been a privilege of well-resourced healthcare systems. A blood test costing a fraction of an MRI doesn’t just diagnose disease. It redistributes the possibility of knowing.
The machine learning component of this research is worth pausing on. The algorithms didn’t just identify disease — they identified disease across genetic diversity. That distinction matters because genetic variation influences how proteins express in the body, how diseases progress, and how biomarkers behave. An algorithm trained exclusively on European-descent populations might miss patterns that present differently in Amerindian or mixed-ancestry genomes. By training models on diverse Latin American data, this study doesn’t just expand access. It expands accuracy for populations that have been invisible in the datasets shaping their own care.
There’s a broader pattern emerging in medical research right now — a reckoning with who gets studied and what gets generalized. We’ve seen it in how sleep apnea presents differently in women over 50, how aging accelerates differently in men, and how dietary interventions for cognitive decline only work when they reach the people who need them. The Latin American blood biomarker study fits squarely into this corrective wave — research that doesn’t just ask “does this work?” but “does this work for everyone?”
Multiple countries. Hundreds of participants. A blood draw and a machine learning model. And suddenly, a diagnostic pathway that was locked behind the doors of wealthy hospitals begins to open — not theoretically, not in a decade, but with tools that already exist.
The quiet revelation in this research isn’t that blood tests work for dementia detection. That finding has been building for years. The revelation is that the science finally went to the populations it had been ignoring — and found that the biology cooperated just fine. The limitation was never in the blood. It was in who we bothered to test.
Feature image by www.kaboompics.com on Pexels
